A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients

ABSTRACT

Introduction

Hexaxim is a hexavalent vaccine approved as primary and booster vaccination in infants 6 weeks and older, protecting against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae type b.

Areas Covered

To evaluate the immunogenicity and reactogenicity (safety) of Hexaxim (Hexyon, Hexacima) in primary and booster vaccine schedules; long-term antibody persistence; concomitant use with other childhood vaccines and use in immunocompromised infants. Hexaxim was found to be noninferior to other licensed hexavalent vaccines, being highly immunogenic for all toxoids/antigens and with an acceptable safety profile. It can be administered concomitantly with other childhood vaccines. Hexaxim can be given as a booster for infants primed with Infanrix Hexa and given in a pentavalent-hexavalent-pentavalent series. Hexaxim elicits a similar immune response and safety profile in human immunodeficiency virus (HIV) positive infants. It has the benefit of being a ready-to-use liquid formulation, minimizing dosage errors and preparation time.

Expert Opinion

Hexaxim has an acceptable safety profile and provides immunity against all six targeted diseases. It is an acceptable alternative to other hexavalent vaccines on the market. Further studies are required on the use of immunocompromised patients as well as the antibody persistence of each of the vaccine components.

KEYWORDS:

• Hexavalent vaccine
• DTaP-IPV-HB-PRP-T
• hexaxim
• hexyon
• diphtheria
• tetanus
• polio
• haemophilus
• hepatitis B

Article highlights

• Twenty-three original articles, containing 29 individual trials were included in this systematic review

• Hexaxim (DT2aP-IPV-Hib-HBV) was licensed based on studies that demonstrated noninferiority in terms of immunogenicity in comparison to already licensed alternatives such as Infanrix Hexa

• DT2aP-IPV-Hib-HBV is a fully liquid ready to use vaccine

• DT2aP-IPV-Hib-HBV provides protection against six childhood diseases

• DT2aP-IPV-Hib-HBV has an acceptable safety profile

• DT2aP-IPV-Hib-HBV elicits a similar immune response and safety profile in Human immunodeficiency virus (HIV) positive infants

Declaration of interest

R Borrow performs contract research on behalf of UK Health Security Agency for GSK, Pfizer and Sanofi Pasteur. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or material discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funding.